UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 12/2017, Volume 318, Issue 23, pp. 2306 - 2316
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Dacarbazine - adverse effects | Follow-Up Studies | Dacarbazine - therapeutic use | Mitosis | Humans | Middle Aged | Male | Electric Stimulation Therapy | Chemoradiotherapy | Glioblastoma - radiotherapy | Glioblastoma - surgery | Antineoplastic Agents, Alkylating - therapeutic use | Disease-Free Survival | Dacarbazine - analogs & derivatives | Survival Analysis | Adult | Female | Aged | Maintenance Chemotherapy | Temozolomide | Antineoplastic Agents, Alkylating - adverse effects | Glioblastoma - drug therapy | Chemotherapy | Usage | Patient outcomes | Dosage and administration | Drug therapy | Glioblastoma multiforme | Cancer | Statistical analysis | Toxicity | Glioblastoma | Central nervous system | Clinical trials | Cell division | Nervous system | Maintenance | Patients | Survival | Scalp | Skin | Portable equipment | Electric fields | Tumors | Index Medicus | Abridged Index Medicus | Original Investigation | Research
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 08/2017, Volume 35, Issue 22, pp. 2490 - 2498
AP26113 | POTENT | ALK INHIBITORS | SAFETY | CERITINIB | BRAIN METASTASES | RESISTANCE | OPEN-LABEL | CHEMOTHERAPY | PROGRESSION | Life Sciences & Biomedicine | Oncology | Science & Technology | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Prospective Studies | Nausea - chemically induced | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Diarrhea - chemically induced | Young Adult | Brain Neoplasms - secondary | Carcinoma, Non-Small-Cell Lung - secondary | Anaplastic Lymphoma Kinase | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Headache - chemically induced | Pyridines - therapeutic use | Crizotinib | Organophosphorus Compounds - adverse effects | Cough - chemically induced | Pyrimidines - administration & dosage | Organophosphorus Compounds - therapeutic use | Treatment Outcome | Brain Neoplasms - drug therapy | Disease Progression | Disease-Free Survival | Retreatment | Receptor Protein-Tyrosine Kinases - genetics | Pyrimidines - therapeutic use | Adolescent | Pyrimidines - adverse effects | Aged | Organophosphorus Compounds - administration & dosage | Carcinoma, Non-Small-Cell Lung - drug therapy | Index Medicus
Journal Article
BMJ : British Medical Journal, ISSN 0959-8138, 10/2015, Volume 351, pp. h5364 - h5364
RESEARCH | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Male | Weight Loss - drug effects | Patient Satisfaction | Hypoglycemic Agents - administration & dosage | Fasting - blood | Injections, Subcutaneous | Postprandial Period | Female | Drug Therapy, Combination | Hypoglycemia - chemically induced | Double-Blind Method | Drug Administration Schedule | Insulin - administration & dosage | Treatment Outcome | Diabetes Mellitus, Type 2 - blood | Liraglutide - adverse effects | Aged | Liraglutide - administration & dosage | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Insulin - adverse effects | Index Medicus | Abridged Index Medicus | glycemic control | once-daily lixisenatide | basal insulin | Endokrinologi och diabetes | adding liraglutide | open-label trial | parallel-group | statement | european association | position | blood-glucose control | Endocrinology and Diabetes | exenatide
Journal Article
The lancet oncology, ISSN 1470-2045, 2014, Volume 15, Issue 8, pp. 862 - 873
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | ras Proteins - genetics | Colonic Neoplasms - genetics | Proto-Oncogene Proteins p21(ras) | Adenocarcinoma - pathology | Colonic Neoplasms - drug therapy | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Diarrhea - chemically induced | Colonic Neoplasms - surgery | Fluorouracil - therapeutic use | Antibodies, Monoclonal, Humanized - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Infusions, Intravenous - adverse effects | Adult | Female | Leucovorin - therapeutic use | Adenocarcinoma - genetics | Chemotherapy, Adjuvant | Cetuximab | Antibodies, Monoclonal, Humanized - adverse effects | Drug Eruptions - etiology | Exons - genetics | Proto-Oncogene Proteins - genetics | Adenocarcinoma - drug therapy | Mucositis - chemically induced | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Colonic Neoplasms - pathology | Intention to Treat Analysis | Aged | Neoplasm Staging | Organoplatinum Compounds - therapeutic use | Organoplatinum Compounds - adverse effects | Adenocarcinoma - surgery | Prevention | Care and treatment | Chemotherapy | Colon cancer | Hospitals | Leucovorin | Product development | Cancer | Index Medicus | Life Sciences
Journal Article
BMC cancer, ISSN 1471-2407, 05/2019, Volume 19, Issue 1, pp. 494 - 494
REGRESSION | SURGERY | OPEN-LABEL | OXALIPLATIN | DOCETAXEL | BREAST-CANCER | CAPECITABINE | Pertuzumab | NEOADJUVANT CHEMOTHERAPY | Gastro-esophageal junction cancer | Perioperative chemotherapy | HER2 | Gastric cancer | Trastuzumab | Life Sciences & Biomedicine | Oncology | Science & Technology | Antineoplastic Agents, Immunological - administration & dosage | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Male | Antineoplastic Agents - therapeutic use | Young Adult | Fluorouracil - therapeutic use | Netherlands | Antibodies, Monoclonal, Humanized - administration & dosage | Aged, 80 and over | Esophageal Neoplasms - mortality | Adult | Female | Neoadjuvant Therapy | Republic of Korea | Antibodies, Monoclonal, Humanized - therapeutic use | Trastuzumab - therapeutic use | Esophagogastric Junction - pathology | Treatment Outcome | Trastuzumab - administration & dosage | Capecitabine - therapeutic use | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Perioperative Period | Cisplatin - therapeutic use | Antineoplastic Agents, Immunological - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Progression-Free Survival | Aged | Esophageal Neoplasms - drug therapy | Stomach Neoplasms - mortality | Adenocarcinoma - mortality | Chemotherapy | Usage | Gastrointestinal cancer | Dosage and administration | Comparative analysis | Drug therapy | Cancer | Immunohistochemistry | Care and treatment | Oncology, Experimental | Gastrointestinal system | Clinical trials | Metastasis | Research | Stomach cancer | Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 11/2017, Volume 390, Issue 10109, pp. 2266 - 2277
BREAST-CANCER | BLADDER-CANCER | LUNG-CANCER | 2ND-LINE THERAPY | TRANSITIONAL-CELL-CARCINOMA | FOLLOW-UP | OPEN-LABEL | FACTOR RECEPTOR-2 | II TRIAL | ENDOTHELIAL GROWTH-FACTOR | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Carcinoma, Transitional Cell - mortality | Prognosis | Humans | Middle Aged | Male | Neoplasm Invasiveness - pathology | Urinary Bladder Neoplasms - pathology | Adult | Female | Urinary Bladder Neoplasms - mortality | Double-Blind Method | Risk Assessment | Docetaxel | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Urinary Bladder Neoplasms - drug therapy | Disease-Free Survival | Taxoids - administration & dosage | Carcinoma, Transitional Cell - pathology | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Internationality | Neoadjuvant Therapy - methods | Carcinoma, Transitional Cell - drug therapy | Survival Analysis | Aged | Neoplasm Staging | Antimitotic agents | Care and treatment | Carcinoma | Analysis | Clinical trials | Product development | Metastasis | Antineoplastic agents | Cancer | Cytotoxicity | Oncology | Patients | Cancer therapies | Evidence-based medicine | Metastases | Angiogenesis | Chemotherapy | Platinum | Medical prognosis | Ligands | Clinical medicine | Urothelial carcinoma | Vascular endothelial growth factor | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article
Journal of psychosomatic research, ISSN 0022-3999, 01/2019, Volume 116, pp. 25 - 30
Pain | Open-label placebos | Dispositional optimism | Personality-related variables | Individual differences | Life Sciences & Biomedicine | Psychiatry | Science & Technology | Young Adult | Optimism - psychology | Placebo Effect | Humans | Middle Aged | Adolescent | Adult | Female | Male | Aged | Research Design | Variables | Analgesia | Heat | Pain perception | Tolerance | Personality | Optimism | Randomized controlled trials | Index Medicus
Journal Article
Alimentary pharmacology & therapeutics, ISSN 0269-2813, 11/2010, Volume 32, Issue 10, pp. 1228 - 1239
Gastroenterology & Hepatology | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Science & Technology | Gastroenterology. Liver. Pancreas. Abdomen | Stomach. Duodenum. Small intestine. Colon. Rectum. Anus | Digestive system | Pharmacology. Drug treatments | Biological and medical sciences | Medical sciences | Other diseases. Semiology | Humans | Abscess | Antibodies, Monoclonal - adverse effects | Male | Treatment Outcome | Fistula | Antibodies, Monoclonal, Humanized | Anti-Inflammatory Agents - adverse effects | Infliximab | Efficiency | Crohn Disease - drug therapy | Quality of Life | Work | Adult | Female | Adalimumab | Wound Healing - drug effects | Clinical trials | Care and treatment | Crohn's disease | Analysis | Index Medicus
Journal Article
Trials, ISSN 1745-6215, 01/2016, Volume 17, Issue 1, pp. 2 - 2
Pilot | Vulval | Multi-armed | Therapy | Pragmatic | Dermatology | Randomised controlled trial | Open-label | Erosive lichen planus | Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Data Interpretation, Statistical | Pilot Projects | Vulvar Diseases - drug therapy | Outcome Assessment (Health Care) | Vulvar Diseases - psychology | Humans | Clinical Protocols | Lichen Planus - psychology | Quality of Life | Female | Lichen Planus - drug therapy | Care and treatment | Analysis | Clinical trials | Research | Lichen planus | Health aspects | Immunosuppressive agents | Index Medicus
Journal Article